Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
For patients with peripheral non-small cell lung cancer receiving stereotactic body radiation therapy, respiratory motion often causes target volume deviation and compromises dose accuracy to tumors and nearby organs at risk. Current standard immobilization methods have limited ability to stabilize deep breathing patterns. This single-center translational study uses an integrated body position and breath-holding device, enrolling 50 eligible patients who will undergo 4DCT scans both with and without the device while keeping their clinical SBRT treatment plan unchanged. We will compare tumor motion amplitude, target coverage, conformity index and organ dose parameters between the two scanning states, to verify the device's feasibility, safety and value in improving treatment precision, providing clinical evidence for wider application in lung SBRT.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Tianjin, Porcelana, 300000
- Tianjin Medical University Cancer Institute and Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Voluntarily participate and sign written informed consent
- Age ≥18 years, gender unlimited
- Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT
- Males or females of childbearing age willing to take contraceptive measures during the trial
- Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after
Exclusion Criteria:
- Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization.
- Currently participating or planning to participate in other clinical trials.
- Refuse or be unable to sign the informed consent form for this trial.
- Patients with central or ultra-central lung cancer.
- Patients planned to receive SBRT for multiple pulmonary lesions.
- Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Single Arm - Novel Respiratory Immobilization
All enrolled patients receive 4DCT with and without the device |
A novel immobilization device used for respiratory motion management during lung stereotactic body radiation therapy |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean respiratory motion amplitude of GTV and organs at risk (OARs) measured on 4DCT before and after abdominal pressure immobilization
Periodo de tiempo: through study completion, an average of 1 year
|
Respiratory motion amplitude (maximum displacement) of gross tumor volume (GTV) and organs at risk (OARs) will be contoured and extracted from pre-abdominal-pressure 4DCT and post-abdominal-pressure 4DCT. The difference in motion amplitude between the two states will be compared to evaluate the feasibility and effectiveness of the novel abdominal pressure positioning membrane for lung SBRT. |
through study completion, an average of 1 year
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Conformity index (CI) of SBRT planning target volume (PTV)
Periodo de tiempo: At the time of SBRT plan design, prior to treatment delivery
|
CI of PTV calculated from SBRT dose distribution after abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
|
Coverage of planning target volume (PTV)
Periodo de tiempo: At the time of SBRT plan design, prior to treatment delivery
|
PTV coverage calculated from SBRT dose distribution after abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
|
Maximum relative dose at 2 cm outside the PTV boundary (D2cm)
Periodo de tiempo: At the time of SBRT plan design, prior to treatment delivery
|
Percentage of maximum dose at the region 2 cm outside PTV boundary on SBRT plan |
At the time of SBRT plan design, prior to treatment delivery
|
|
Volume of normal ipsilateral lung receiving ≥20Gy,15Gy,10Gy and 5Gy (V20,V15, V10, V5)
Periodo de tiempo: At the time of SBRT plan design, prior to treatment delivery
|
Dose-volume histogram parameters of normal treated lung from abdominal-pressure SBRT plan |
At the time of SBRT plan design, prior to treatment delivery
|
|
Maximum dose (Dmax) to organs at risk including spinal cord, heart and esophagus
Periodo de tiempo: At the time of SBRT plan design, prior to treatment delivery
|
Dmax of OARs derived from SBRT dose plan under abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- bc20261997
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
This is an exploratory feasibility study, and no public sharing of individual patient data is planned.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .